Clinical trial NCT01968226: TRACER RGD-K5 Carotid Plaque Imaging Study
Official title: An Exploratory, Phase II, Open Label, Single-Center, Non-Randomized Study Of [F-18] RGD-K5 Positron Emission Tomography (PET) In Participants With Carotid Artery Stenosis
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Carotid Artery Disease
Carotid Stenosis
Keywords: carotid artery disease
carotid stenosis
carotid endarterectomy
RDG-K5
PET imaging
Lead sponsor: The Cleveland Clinic
Sponsor class: OTHER
First posted: 2013-10-23
Enrollment: 3
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: The purpose of this study is to investigate the ability of the compound\[F-18\]RGD-K5, when used as a tracer during PET (positron emission tomography) imaging, to detect regions of unstable atherosclerotic plaque in the carotid artery of subjects being considered for carotid endarterectomy (CEA),and to confirm this ability through histological studies of samples of carotid artery plaques that will be collected during the planned carotid surgery.

Detailed description: Patients will be chosen for the study based on presence of carotid artery stenosis ascertained by CTA and carotid artery ultrasound. Patients will receive and intravenous injection of the radiolabeled PET tracer,\[F-18\]RGD-K5, and will undergo PET imaging of their carotid arteries bilaterally. PET images will be analyzed to determine the standard uptake value (SUV) of \[F-18\]RGD-K5 uptake by the carotid artery plaque and this will be compared to the SUV of the background (blood pool in the aorta). This will be expressed as a target to background ratio (TBR). Investigators expect to find a significant uptake of \[F-18\]RGD-K5 by carotid artery palque and investigators therefore expect to find a TBR that is significantly \>1. Investigators also expect to find that plaque from patients who show a TBR \>1 will also be enriched for histologic markers for inflammation and angiogenesis.

Eligibility criteria: Inclusion Criteria:

* Participant is a female or male of any race/ethnicity \>18 years old at the time of the investigational product administration
* Participant or participant's legally acceptable representative provides written informed consent
* Participant is capable of complying with study procedures
* Participant has known carotid artery stenosis of \>50% luminal diameter based on carotid ultrasound or computed tomography angiography (CTA), as stated in official clinical report or as measured by PI if no quantitative assessment appears in the report, and who is deemed to be a surgical candidate for endarterectomy
* Participant has had a carotid ultrasound and/or computed tomography angiography (CTA) and the report is available for collection
* Participant has had or is scheduled to have a carotid CT angiogram for plaque localization within 60 days of signing ICF (or else scheduled CTA must be performed on a separate day and prior to the investigational PET procedure)
* Participant has consented to have an endarterectomy
* Participant will be scheduled for an investigational\[F-18\]RGD-K5 PET/CT scan within 4 weeks prior to endarterectomy
* Participant must have renal functions values as defined by laboratory results within the following ranges:

  * Serum creatinine ≤ 1.5 mg/dL
  * Estimated glomerular filtration rate (eGFR): ≥ 45mL/min

Exclusion Criteria:

* Female participant is nursing
* Female participant is pregnant
* Participant has been involved in an investigative, radioactive research procedure within the past 14 days
* Participant has any other condition or personal circumstance that, in the judgment of the investigator, might interfere with the collection of complete data or data quality
* Participant has a history or current evidence of any condition, therapy, lab abnormality that, in the opinion of the study investigator or treating physicians might confound the results of the study or poses an additional risk to the participants by their participation in the study

Primary outcomes:
measure: Target to Background Ratio (TBR)
timeFrame: Baseline
Secondary outcomes:
Other outcomes:
Locations:
city: Cleveland
country: United States
facility: Cleveland Clinic
state: Ohio
Study officials:
affiliation: The Cleveland Clinic
name: Balaji Tamarappoo, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References: